Bio-Works Board of Directors

Shareholding info last updated 2020-04-24
Peter Ehrenheim

Peter Ehrenheim

Chairman of the Board
  • Elected to the board: 2019-09-09

Operative background from Pharmacia Biotech, Amersham and GE Healthcare. General manager for Separations Division 1999-2006. From 2006-2011 General manager for GE’s Life Sciences Business which was recently acquired by Danaher. From 2011 entrepreneur with different companies and board roles. Presently chairman in Medcap AB, Boule Diagnostics AB and Sophion A/S. Also Director in Biotage AB.

Independence: Independent in relation to the company and the company management, independent in relation to major shareholders.

  • Shares: 162 537 and 439 868 via Färjsundet AB
Thomas Eklund

Thomas Eklund

Board director
  • Elected to the board: 2019-09-09

Independent advisor, board member and investor. Head of Investor Growth Capital 2001 to 2013. Board member and lead investor in Swedish Orphan, Carmel Pharma, Entific Medical, Vardapoteket and Memira. Previously Investment Director at AAC Capital and Director Handelsbanken Market, corporate finance. Presently chairman in Biotage AB and Sedana Medical AB and director in Boule Diagnostics, Immedica Pharma AB, Swedencare AB and Surgical Science AB. Advisor to Impilo AB and Investor AB.

Independence: Independent in relation to the company and the company management, independent in relation to major shareholders.

  • Shares: 555 556
Kirsti Gjellan

Kirsti Gjellan

Board director
  • Elected to the board: 2018-05-18

More than 30 years of experience from Pharmaceutical industry covering Discovery, Proof of Concept, Pharmaceutical Development, Quality Operations in Manufacturing, EHS, Right First Time/Lean/Six Sigma and site leader management as well as managing director. All work experience has been generated in the dynamic between local and global organizations to create the most business value. Has worked as a Leader/manager and Change Agent since 1989.

Independence: Independent in relation to the company and the company management, independent in relation to major shareholders.

  • Shares: 12 856
  • Warrants: 15 000
Patrick Van De Velde

Patrick Van De Velde

Board director
  • Elected to the board: 2017-06-07

Current General Manager and Board Member Promega Biotech AB, previous head of marketing Europe at GE Health and sales & business development manager at Sigma Aldrich Sweden.

Independence: Independent in relation to the company and the company management, independent in relation to major shareholders.

  • Shares: 15 500
  • Warrants: 15 000
Johan Sedihn

Johan Sedihn

Board director
  • Elected to the board: 2020-05-15

Johan Sedihn is a Master of Science in Industrial Economics from the Technical University of Linköping. He has more than 25 years of experience in the medical technology industry, most of his time in the Elekta Group. He has been involved in building operations during Elekta's growth in roles such as Executive VP Oncology and Chief Operating Officer. For 13 years, Johan was part of Elekta's Group Management and he was also CEO of subsidiaries in Sweden and the UK, and Chairman of the Board of dozens of subsidiaries around the world. Johan has experience from several board assignments, two of which are currently SyntheticMR AB (publ) where he is chairman of the board and Dirac Research AB where he is a board member. Both of these companies' growth journeys involve similar challenges to those that Bio-Works faces. Johan Sedihn has been living in the UK since 2005.

Independence: Independent in relation to the company and the company management, independent in relation to major shareholders.

Peter Nählstedt

Peter Nählstedt

Board director
  • Elected to the board: 2020-05-15

Peter Nählstedt has more than 20 years of operative experience from leading positions in life science and industry. He provides consulting services and advisory in business development in the Life Sciences and technology area. During his time as CEO of Probi between 2014-2018 the company grew from 100 MSEK to 600 MSEK. Earlier experience include 4 years at Trelleborg Marine Systems and 8 years at GE Healthcare Life Science of which several years were spent in the US leading its Bioprocess business. Board Director at SenzaGen AB (publ), Chairman of the board at Double Good AB and Supersynbiotics AB.

Independence: Independent in relation to the company and the company management, independent in relation to major shareholders.

  • Shares: 9450
Yong Chul Shin

Yong Chul Shin

Substitute
  • Elected to the board: 2017-06-07

Current CEO and Chairman of Amicogen Inc. South Korea. Former professor of Gyungsang National University, former committee member of the Korean Food and Drug Administration. Previous journal editor of the Korea Society for Microbiology and Biotechnology.

Independence: Independent in relation to the company and the company management, independent in relation to major shareholders.

  • Shares: 3 007 896 (via Amicogen Inc.)
Thomas Pollare

Thomas Pollare

Substitute
  • Elected to the board: 2013-09-24

Former CEO Global Medical Investments, former partner with venture capital firm 3i. VP roles at Pharmacia and Schering-Plough Research Institute. Board experience in major corporations as well as start-ups and venture investing.

Independence: Independent in relation to the company and the company management, independent in relation to major shareholders.

  • Shares: 145 639 (via Oncolution AB)
  • Warrants: 15 000
Copyrights © 2020 All Rights Reserved by Bio-Works.